Skip to main content

Table 1 Baseline characteristics

From: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

Variables

Number of patients (N = 183)

No

%

Age, median (range)

46 (25–71)

 

Histology

  

 Invasive ductal carcinoma

167

91.3

Premenopausal/Postmenopausal

109/74

59.6/40.4

Regimen of Neoadjuvant Chemotherapy

  

 Concurrent anthracycline + taxane

128

69.9

 Sequential anthracycline + taxane

47

25.7

 HER-2 directed agent containing regimen

10

5.5

 Doxorubicin plus cyclophosphamide

1

0.5

Type of Surgery

  

 Breast conserving surgery

104

56.8

 Mastectomy

79

43.2

Initial Clinical Stage

  

 IIA

3

1.6

 IIB

27

14.8

 IIIA

94

51.4

 IIIB

26

14.2

 IIIC

33

18.0

Hormone receptor and HER2 expression status

  

 Hormone receptor (+)

106

57.9

 HER2 (+)

58

31.7

Pathologic Stage

  

 yp0

22

12.0

 ypIA

41

22.4

 ypIIA

42

23.0

 ypIIB

22

12.0

 ypIIIA

38

20.8

 ypIIIB

2

1.1

 ypIIIC

16

8.7

Adjuvant therapy

  

 Radiation therapy

158

86.3

 Chemotherapy

62

33.9

 Trastuzumab

55

94.8 % of patients with HER2 positive tumor

 Hormonal therapy

103

97.1 % of patients with HR positive tumor

  1. HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer